Cancer ResearchReview ArticlePaywall

Chemo Plus Surgery Falls Short of Chemoradiotherapy for Locally Advanced Cervical Cancer

A Cochrane review of 3 trials in 1,326 women finds neoadjuvant chemo plus surgery doesn't beat chemoradiotherapy and likely raises severe acute toxicity.

Sunday, November 22, 2026 0 views
Published in Cochrane Database Syst Rev
A radiation oncology treatment room with a linear accelerator and patient table in a hospital

Summary

Chemoradiotherapy is the standard treatment for locally advanced cervical cancer, but it is toxic and radiotherapy is not available everywhere. Some have proposed giving chemotherapy first and then performing radical surgery instead. This Cochrane review pooled three randomized trials involving 1,326 women to compare the two approaches. Five-year overall survival may be similar between the treatments, though the evidence is low certainty. Evidence on disease-free and progression-free survival is very uncertain, and progression-free survival pointed toward worse results with chemo plus surgery. Severe acute side effects (grade 3 or higher) were probably more common with chemo plus surgery. Quality of life at 24 months looked similar. The authors conclude the evidence does not support chemo plus surgery as an alternative, and chemoradiotherapy remains standard where good radiotherapy exists. Where it does not, evidence is still too thin to recommend the surgical route. This summary is based on the abstract only.

0:00--:--

Detailed Summary

Why this matters: Cervical cancer treatment decisions carry lifelong consequences for women, and radiotherapy is not accessible everywhere. Chemoradiotherapy (CRT) is standard for locally advanced disease but is toxic, so an alternative of neoadjuvant chemotherapy (NACT) followed by radical surgery has been proposed.

What was studied: This Cochrane systematic review searched CENTRAL, MEDLINE, Embase and ClinicalTrials.gov through May 2026. It included only randomized trials in women with FIGO 2018 stage IB3 to IVA disease comparing NACT plus radical surgery with CRT. Three trials (four reports) with 1,326 women were meta-analyzed using random effects, with risk of bias assessed by RoB 1 and certainty graded by GRADE.

Key results: Five-year overall survival may differ little (HR 1.11, 95% CI 0.90 to 1.36; 2 trials, 1,259 women; low certainty). Disease-free survival was very uncertain (HR 1.28, 0.97 to 1.69; single trial). Progression-free survival was worse with NACT plus surgery, with a confidence interval excluding no difference (HR 1.37, 1.07 to 1.75). This came from a single trial of 626 women and is very low certainty. Grade 3 or higher acute toxicity was probably increased (RR 1.82, 1.45 to 2.29; moderate certainty). Late severe toxicity was very uncertain (RR 0.71, 0.50 to 1.01). Quality of life at 24 months showed little to no difference (low certainty).

Implications: The authors conclude the evidence does not support NACT plus surgery as a substitute for CRT. CRT stays the standard where high-quality radiotherapy exists. Where it does not, evidence remains insufficient to recommend the surgical pathway.

Caveats: Few trials contributed to each outcome, and certainty was very low to moderate. The authors note the trials used older radiotherapy techniques with high cross-over rates, which limits conclusions about late toxicity. This summary is based on the abstract only.

Key Findings

  • Five-year overall survival may differ little between NACT plus surgery and CRT (HR 1.11, 0.90-1.36; low-certainty; 2 trials, 1,259 women).
  • Progression-free survival was worse with NACT plus surgery, with a CI excluding no effect (HR 1.37, 1.07-1.75), but this came from one trial of 626 women and is very low certainty.
  • Grade 3 or higher acute toxicity was probably higher with NACT plus surgery (RR 1.82, 1.45-2.29; moderate certainty).
  • Late severe toxicity evidence is very uncertain (RR 0.71, 0.50-1.01); quality of life at 24 months showed little difference.
  • Authors conclude CRT remains standard; evidence is insufficient to recommend NACT plus surgery even where radiotherapy is lacking.

Methodology

Cochrane systematic review and random-effects meta-analysis (inverse variance) of randomized trials comparing NACT plus radical surgery with CRT in women with FIGO 2018 stage IB3-IVA cervical cancer. Three RCTs (1,326 women) were included; bias was assessed with RoB 1 and certainty with GRADE. Searches ran through May 2026 with no language restrictions.

Study Limitations

This summary is based on the abstract only, so trial-level details were not reviewed. Only three trials contributed, several outcomes came from a single trial, and certainty was often low or very low because of bias, indirectness and imprecision. Older radiotherapy techniques and high cross-over rates limit applicability, especially for late toxicity.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: